BURLINGTON, Mass., Aug. 6, 2014 /PRNewswire/ -- Decision Resources Group finds that at one year post-launch in the United States, over two thirds of surveyed U.S. medical oncologists have prescribed Bayer HealthCare's alpha-emitting radiopharmaceutical Xofigo. The majority of current non-prescribers indicated that they expect to prescribe Xofigo to their metastatic castrate-resistant prostate cancer (mCRPC) patients within the next six months. Notably, at one year post-launch, nearly one-half of surveyed respondents indicated that the need for referral to a licensed physician in an approved nuclear medicine facility would moderately impact their prescribing decisions for Xofigo.
Other key findings from report entitled LaunchTrends®: Xofigo (Prostate Cancer) (Wave 3) (US):
- Satisfaction with Xofigo: The majority of surveyed medical oncologists who have prescribed Xofigo for docetaxel-naive and docetaxel-pretreated symptomatic mCRPC indicated a moderate to high level of satisfaction with the agent.
- Advantages over current therapies: Xofigo's efficacy data, bone-targeted mechanism of action, limited treatment duration and safety profile are among its top perceived advantages over other currently available therapies, according to our survey results.
- Prescribing patterns: A majority of surveyed medical oncologists indicated that they would most likely prescribe Xofigo to symptomatic mCRPC patients who had been pretreated with docetaxel and Zytiga. Nevertheless, over a third of respondents stated that they would most likely prescribe Xofigo to their docetaxel-naive mCRPC patients with symptomatic bone metastases and who are unwilling to receive chemotherapy.
- Combination approaches: More than one-third of Xofigo prescribers indicated that they would prescribe Xofigo in combination with currently available agents, most likely Zytiga or Lupron/Eligard; however, a variety of other current therapies were also cited by these respondents.
Comments from Decision Resources Group Analyst Jennifer Bamford:
- "Lack of familiarity, cost and the need to administer Xofigo at a specialist nuclear medicine facility are the standout constraints on Xofigo prescribing in symptomatic mCRPC, according to surveyed oncologists."
- "Only a third of respondents reported no contact with any Xofigo sales representative at one year post-launch, compared with the majority of respondents in prior waves of research. Respondents indicated a high satisfaction with Xofigo sales representatives' performance, including their ability to address questions regarding product logistics."
About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.
All company, brand, or product names contained in this document may be trademarks or
registered trademarks of their respective holders.
For more information, contact:
Decision Resources Group
SOURCE Decision Resources Group